Proteome pulls out of prostate test
Tuesday, 15 July, 2008
Proteome Systems [ASX: PXL] has stopped development of a prostate cancer diagnostics test, after concluding that bringing the product to market would take too long.
Proteome had discovered cancerous prostate tissues demonstrate increased expression of Human Carcinoma Antigen [HCA], and developed an assay for detection of HCA in semen samples.
But the company concluded that developing the assay for commercialisation would take too long and consume too many resources.
A spokesperson for the company said Proteome was committed to projects with near-term revenue potential.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
